COP vs NBIX · P/E 19, rev $58.94B vs P/E 45, rev $2.36B
ConocoPhillips (COP) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
COP currently screens at market cap $135.49B and trailing P/E 18.8. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the COP and NBIX stock pages for the full models.
Not investment advice.